Lyell Immunopharma (NASDAQ:LYEL) Trading Down 6.7% – Should You Sell?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) shares traded down 6.7% during trading on Friday . The stock traded as low as $36.00 and last traded at $36.02. 25,191 shares changed hands during mid-day trading, a decline of 65% from the average session volume of 72,953 shares. The stock had previously closed at $38.60.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on LYEL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Monday, September 1st. Finally, HC Wainwright upgraded shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their target price for the stock from $20.00 to $45.00 in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $45.00.

Lyell Immunopharma Trading Down 9.1%

The company’s fifty day simple moving average is $23.48 and its 200 day simple moving average is $15.95. The firm has a market capitalization of $745.31 million, a P/E ratio of -1.52 and a beta of -0.11.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.81) by $0.68. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million. On average, analysts predict that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in LYEL. Marshall Wace LLP bought a new stake in shares of Lyell Immunopharma during the second quarter valued at approximately $94,000. Bridgeway Capital Management LLC bought a new position in Lyell Immunopharma in the second quarter worth $159,000. Clarius Group LLC lifted its position in Lyell Immunopharma by 4.3% during the third quarter. Clarius Group LLC now owns 19,958 shares of the company’s stock valued at $324,000 after buying an additional 820 shares during the period. Two Sigma Investments LP boosted its holdings in shares of Lyell Immunopharma by 107.0% during the 3rd quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock valued at $338,000 after buying an additional 10,768 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Lyell Immunopharma during the 2nd quarter valued at $258,000. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.